QURE - CIK 0001590560
uniQure N.V. trades as QURE and has a market capitalization of $1.70 B, making it the #2229 largest US-listed company by market value. In its fiscal 2017 annual report the company posted revenue of $13.11M, down 47.8% from the prior year and net income of -$199.00M. This page tracks uniQure N.V. through 888 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-12 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-08 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| SCHEDULE 13G/A | - | 2026-04-30 |
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | uniqure BV
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease | uniqure BV
uniQure to Announce First Quarter 2026 Financial Results | uniqure BV
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease | uniqure BV
uniQure Announces 2025 Financial Results and Provides Recent Company Updates | uniqure BV
The largest companies sharing uniQure N.V.'s SEC industry classification (pharmaceutical preparations).
uniQure N.V. (QURE) has a market capitalization of $1.70 B as of 2026-06-10, ranking #2229 among US-listed companies.
uniQure N.V. reported revenue of $13.11M for fiscal year 2017, a decrease of 47.8% year over year.
In its latest fiscal year uniQure N.V. reported a net loss of $199.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.